Latest Industry Insights

In bioanalysis, AI could alleviate preclinical and clinical bioanalytical data processing and analysis. Here, Mary Belfast from Teva Branded Pharmaceuticals, discusses some of the latest guidelines on AI implementation and validation in bioanalysis.

Dr. Sergio Pérez Rosal explains why, in his opinion, “hope is not lost” and the therapeutic potential of psychedelics for the treatment of psychiatric disorders could still be unlocked. But what happens next must be firmly rooted in science.

We sat down with Professor Peter Van Eenoo, director of the Doping Control Laboratory (DoCoLab), part of the University of Ghent, Belgium, to discuss the intricacies of anti-doping testing and the challenges faced in catching sporting cheats.

In this interview, Tola Olorunnisola, senior vice president and general manager at Avantor, delves into how AI and automation could put the Lab of the Future within our grasp, enabling scientific breakthroughs and revolutionizing the drug development process.

Elsevier’s “Insights 2024: Attitudes toward AI” report reveals how researchers feel about AI and what is needed to increase trust in these tools. Here, Mirit Eldor, managing director, life sciences at Elsevier discusses these findings further.

At SLAS Europe 2024, Technology Networks had the pleasure of speaking with Jeroen Verheyen, CEO of Semarion, to discuss their award-winning work and how technological innovations advance research.

Two winners earned the New Product Award at SLAS Europe 2024: SEED Biosciences’ Dispen3D and Cryologyx’s PlateReady™. Technology Networks spoke with CEO of CryoLogyx Tom Congdon to learn more about their award-winning new product.

Western blotting is a staple technique in many laboratories but can be time consuming and inconsistent. Technology Networks spoke with Harsha Rao to learn more about Stain-Free western blotting and the advantages of total protein normalization.

To learn more about the FDA's pending decision on MDMA-assisted therapy for PTSD, Technology Networks interviewed Dr. Sam Clark, CEO of Terran Biosciences, who leads one of the industry’s largest psychedelic development programs.

At SLAS Europe 2024, Technology Networks had the pleasure of speaking with Tim Dillon, market manager (Nordics) at Mettler-Toledo Rainin, to learn about how more sustainable options can be implemented into scientists’ daily workflows.